ArticleMicrobiology spectrum2025
Clinical characteristics and risk factors associated with severe community-acquired pneumonia infected by
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical Characteristics and Machine Learning-Based Severity Classification ofInfection and drug resistance · 2026Article
- Incidence, clinical characteristics, and risk factors of acute kidney injury in patients withFrontiers in cellular and infection microbiology · 2026Article
- Severe pneumonia caused byFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The study aimed to describe the clinical features of psittacosis pneumonia and identify risk factors associated with severe psittacosis pneumonia. We retrospectively collected data from patients with psittacosis pneumonia, confirmed by metagenomic next-generation sequencing (mNGS) from January 2022 to June 2024 and analyzed differences between severe and non-severe groups. A total of 24 patients (eight severe/16 non-severe) were diagnosed with psittacosis, and 33.3% had severe psittacosis pneumonia. The levels of white blood cells (WBCs), neutrophils, neutrophil-to-lymphocyte ratio (NLR), hypersensitive C-reactive protein (hs-CRP), and procalcitonin (PCT) and the detection rate of fungi by mNGS were significantly higher in the severe group than in the non-severe group. The length of stay and omadacycline use were longer in patients of the severe group when compared to the non-severe group. Receiver operating characteristic (ROC) curves indicated that NLR had a better predictive value of severe conditions than PCT and hs-CRP. Patients with psittacosis pneumonia have a high rate of severe disease, and NLR may be a useful tool to promptly ascertain the severity of the disease and optimal therapies for better outcomes. IMPORTANCE: This study explores the clinical features of psittacosis pneumonia and identifies key factors that may predict the severity of the disease. By analyzing data from 24 patients diagnosed using metagenomic next-generation sequencing (mNGS), the research uncovers important differences between severe and non-severe cases. The study finds that patients with severe psittacosis pneumonia have elevated levels of white blood cells (WBCs), neutrophils, neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (hs-CRP), and procalcitonin (PCT), as well as a higher detection rate of fungi. Notably, the NLR emerges as a strong predictor of severe disease, suggesting its potential as an early diagnostic tool. These findings provide valuable insights that can help healthcare providers identify high-risk patients more quickly, allowing for timely interventions and improved management of the disease. Ultimately, this research could lead to better outcomes by guiding treatment decisions and enhancing our understanding of psittacosis pneumonia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.